PHAR vs. MOR, CRNX, ALVO, HCM, AMRX, CPRX, BHC, OGN, XENE, and MIRM
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Organon & Co. (OGN), Xenon Pharmaceuticals (XENE), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.
Pharming Group vs. Its Competitors
Pharming Group (NASDAQ:PHAR) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Pharming Group has higher revenue and earnings than MorphoSys. Pharming Group is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Pharming Group has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Pharming Group currently has a consensus price target of $30.00, indicating a potential upside of 195.28%. Given Pharming Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pharming Group is more favorable than MorphoSys.
Pharming Group has a net margin of -4.14% compared to MorphoSys' net margin of -226.79%. Pharming Group's return on equity of -6.01% beat MorphoSys' return on equity.
In the previous week, Pharming Group had 2 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Pharming Group and 1 mentions for MorphoSys. Pharming Group's average media sentiment score of 0.57 beat MorphoSys' score of -0.71 indicating that Pharming Group is being referred to more favorably in the media.
Summary
Pharming Group beats MorphoSys on 12 of the 16 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
This page (NASDAQ:PHAR) was last updated on 7/8/2025 by MarketBeat.com Staff
Free PHAR Stock Alerts